Published in AIDS Weekly, April 23rd, 2001
"Questions exist about whether testing of preventive HIV-1 vaccines, which will require rapid recruitment and retention of cohorts with high HIV-1 seroincidence, is feasible in the United States," said G.R. Seage, III, and colleagues in the HIVNET Vaccine Preparedness Study group at the Harvard School of Public Health.
They conducted a prospective cohort study in 1995-1997 among...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.